Eukles Asset Management Has $3.01 Million Stake in Zoetis Inc. (NYSE:ZTS)

Eukles Asset Management reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 5.6% during the 4th quarter, HoldingsChannel reports. The firm owned 18,497 shares of the company’s stock after selling 1,097 shares during the quarter. Zoetis comprises about 1.3% of Eukles Asset Management’s investment portfolio, making the stock its 26th biggest position. Eukles Asset Management’s holdings in Zoetis were worth $3,014,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Darwin Wealth Management LLC bought a new stake in Zoetis in the 3rd quarter valued at $31,000. First Personal Financial Services acquired a new position in shares of Zoetis during the third quarter valued at about $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the third quarter valued at about $33,000. Dunhill Financial LLC grew its position in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares in the last quarter. Finally, Fortitude Family Office LLC increased its stake in Zoetis by 1,387.5% during the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 1.6 %

Shares of ZTS opened at $171.37 on Monday. The company has a market capitalization of $77.32 billion, a P/E ratio of 32.21, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The business’s 50 day simple moving average is $169.26 and its 200-day simple moving average is $179.22. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is presently 37.59%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Morgan Stanley dropped their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average price target of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.